Vor Bio Appoints Dallan Murray as New Chief Commercial Officer
CAMBRIDGE, Mass. — Vor Bio, a cutting-edge clinical-stage biotechnology firm listed on Nasdaq as VOR, has announced the strategic appointment of Dallan Murray as its Chief Commercial Officer, effective immediately. This appointment comes at a vital time for the company as it seeks to enhance its commercial initiatives in the burgeoning field of autoimmune disease treatments.
Expertise and Leadership
“We are excited to bring Dallan aboard as we reach a pivotal moment in our growth trajectory,” expressed Jean-Paul Kress, M.D., the Chief Executive Officer and Chairman of Vor Bio. “With his impressive background in establishing successful commercial frameworks and his expertise in launching innovative products, Dallan will be a fundamental asset as we prepare for the potential commercialization of our leading therapy, telitacicept.”
Dallan Murray possesses over 25 years of extensive experience in guiding commercial strategies and spearheading global product launches within the biotechnology and pharmaceutical sectors. He recently held the role of Executive Vice President and Chief Customer Officer at Sarepta Therapeutics, where he led efforts in commercial and medical affairs, along with expanding their international reach. His leadership at Sarepta propelled the company to achieve nearly $1.8 billion in net product revenues, a significant milestone that underscores his capability in driving commercial success.
Achievements at Sarepta
During his time at Sarepta, Mr. Murray was instrumental in launching key therapies, including the groundbreaking RNA therapy and the first gene therapy aimed at treating Duchenne Muscular Dystrophy. His career also includes impressive exploits at Vertex Pharmaceuticals, where he played a crucial role in the rapid launch of INCIVEK, marking the fastest ascent to $1 billion in biotech history. His marketing influence extended further at Gilead Sciences, Inc., where he managed the launch of VIREAD for hepatitis B.
Vision for Vor Bio
“Vor Bio is at the forefront of an exciting transformation in the treatment of autoimmune diseases,” remarked Mr. Murray. “With telitacicept already approved in China for several autoimmune indications and advancing through pivotal Phase 3 development globally, I am eager to contribute to a vision that aims to bring essential therapies to patients worldwide. I look forward to collaborating with the team to establish a strong commercial and strategic foundation that will secure long-term success for the company.”
About Vor Bio
Vor Bio is a dedicated biotechnology firm focused on innovating treatments for autoimmune diseases. The company’s flagship product, telitacicept, is a novel dual-target fusion protein undergoing rapid Phase 3 clinical development. Vor Bio is committed to addressing serious autoantibody-driven conditions on a global scale, paving the way for a new standard of care.
Company Contacts
For further inquiries, the media and investors can reach out to:
Carl Mauch
Email: cmauch@vorbio.com
Sarah Spencer
Email: investors@vorbio.com
Frequently Asked Questions
Who is Dallan Murray?
Dallan Murray is the newly appointed Chief Commercial Officer at Vor Bio, bringing over 25 years of experience in the biotech industry.
What is telitacicept?
Telitacicept is a novel dual-target fusion protein developed by Vor Bio to treat serious autoimmune diseases.
Where is Vor Bio located?
Vor Bio is based in Cambridge, Massachusetts, focusing on innovative solutions for autoimmune diseases.
What achievements did Dallan Murray have at Sarepta?
At Sarepta, he oversaw significant commercial operations and led the launch of therapies that generated substantial revenues.
How can I contact Vor Bio for more information?
You can reach out via email to their media contact, Carl Mauch, or their investor contact, Sarah Spencer.
